Logo image of NXGL

NEXGEL INC (NXGL) Stock Fundamental Analysis

NASDAQ:NXGL - Nasdaq - US65344E1073 - Common Stock - Currency: USD

2.6899  -0.04 (-1.47%)

Fundamental Rating

3

Taking everything into account, NXGL scores 3 out of 10 in our fundamental rating. NXGL was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NXGL may be in some trouble as it scores bad on both profitability and health. NXGL is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NXGL has reported negative net income.
NXGL had a negative operating cash flow in the past year.
NXGL had negative earnings in each of the past 5 years.
NXGL had a negative operating cash flow in each of the past 5 years.
NXGL Yearly Net Income VS EBIT VS OCF VS FCFNXGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

NXGL's Return On Assets of -30.09% is in line compared to the rest of the industry. NXGL outperforms 42.78% of its industry peers.
NXGL has a Return On Equity (-60.28%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -30.09%
ROE -60.28%
ROIC N/A
ROA(3y)-35.81%
ROA(5y)-46.56%
ROE(3y)-62.13%
ROE(5y)-690.12%
ROIC(3y)N/A
ROIC(5y)N/A
NXGL Yearly ROA, ROE, ROICNXGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

Looking at the Gross Margin, with a value of 35.78%, NXGL is doing worse than 69.52% of the companies in the same industry.
In the last couple of years the Gross Margin of NXGL has grown nicely.
The Profit Margin and Operating Margin are not available for NXGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y266%
GM growth 5YN/A
NXGL Yearly Profit, Operating, Gross MarginsNXGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

NXGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
NXGL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NXGL has more shares outstanding
The debt/assets ratio for NXGL is higher compared to a year ago.
NXGL Yearly Shares OutstandingNXGL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
NXGL Yearly Total Debt VS Total AssetsNXGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

NXGL has an Altman-Z score of -0.01. This is a bad value and indicates that NXGL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.01, NXGL perfoms like the industry average, outperforming 42.78% of the companies in the same industry.
NXGL has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.16, NXGL is in line with its industry, outperforming 54.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z -0.01
ROIC/WACCN/A
WACC8.85%
NXGL Yearly LT Debt VS Equity VS FCFNXGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

NXGL has a Current Ratio of 1.88. This is a normal value and indicates that NXGL is financially healthy and should not expect problems in meeting its short term obligations.
NXGL has a Current ratio of 1.88. This is in the lower half of the industry: NXGL underperforms 67.91% of its industry peers.
NXGL has a Quick Ratio of 1.15. This is a normal value and indicates that NXGL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.15, NXGL is doing worse than 72.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.15
NXGL Yearly Current Assets VS Current LiabilitesNXGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.44% over the past year.
Looking at the last year, NXGL shows a very strong growth in Revenue. The Revenue has grown by 115.85%.
NXGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 64.56% yearly.
EPS 1Y (TTM)17.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
Revenue 1Y (TTM)115.85%
Revenue growth 3Y77.64%
Revenue growth 5Y64.56%
Sales Q2Q%121.64%

3.2 Future

NXGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.50% yearly.
NXGL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.07% yearly.
EPS Next Y71.44%
EPS Next 2Y62.25%
EPS Next 3Y57.37%
EPS Next 5Y48.5%
Revenue Next Year50.22%
Revenue Next 2Y46.25%
Revenue Next 3Y44.56%
Revenue Next 5Y38.07%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NXGL Yearly Revenue VS EstimatesNXGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M
NXGL Yearly EPS VS EstimatesNXGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

NXGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 8.51 indicates a reasonable valuation of NXGL.
Based on the Price/Forward Earnings ratio, NXGL is valued cheaply inside the industry as 95.72% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.19, NXGL is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 8.51
NXGL Price Earnings VS Forward Price EarningsNXGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXGL Per share dataNXGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NXGL's earnings are expected to grow with 57.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62.25%
EPS Next 3Y57.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NXGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXGEL INC

NASDAQ:NXGL (7/11/2025, 8:00:02 PM)

2.6899

-0.04 (-1.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners8.28%
Inst Owner Change0%
Ins Owners14.81%
Ins Owner Change-2.22%
Market Cap20.58M
Analysts82.86
Price Target6.12 (127.52%)
Short Float %0.82%
Short Ratio1.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.96%
Min EPS beat(2)-7.84%
Max EPS beat(2)11.76%
EPS beat(4)2
Avg EPS beat(4)-0.49%
Min EPS beat(4)-7.84%
Max EPS beat(4)11.76%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.29%
Min Revenue beat(2)-0.36%
Max Revenue beat(2)0.94%
Revenue beat(4)3
Avg Revenue beat(4)0.58%
Min Revenue beat(4)-0.36%
Max Revenue beat(4)1.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-40%
EPS NQ rev (3m)-40%
EPS NY rev (1m)-133.33%
EPS NY rev (3m)-566.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.51
P/S 2.01
P/FCF N/A
P/OCF N/A
P/B 3.95
P/tB 6.22
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)0.32
Fwd EY11.76%
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS1.34
BVpS0.68
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.09%
ROE -60.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.78%
FCFM N/A
ROA(3y)-35.81%
ROA(5y)-46.56%
ROE(3y)-62.13%
ROE(5y)-690.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y266%
GM growth 5YN/A
F-Score4
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.15
Altman-Z -0.01
F-Score4
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)166.83%
Cap/Depr(5y)273.19%
Cap/Sales(3y)9%
Cap/Sales(5y)18.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
EPS Next Y71.44%
EPS Next 2Y62.25%
EPS Next 3Y57.37%
EPS Next 5Y48.5%
Revenue 1Y (TTM)115.85%
Revenue growth 3Y77.64%
Revenue growth 5Y64.56%
Sales Q2Q%121.64%
Revenue Next Year50.22%
Revenue Next 2Y46.25%
Revenue Next 3Y44.56%
Revenue Next 5Y38.07%
EBIT growth 1Y0%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.89%
EBIT Next 3Y61.03%
EBIT Next 5YN/A
FCF growth 1Y-12.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.48%
OCF growth 3YN/A
OCF growth 5YN/A